Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06488716 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT06488716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06488716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 16, 2024
Completion date
November 5, 2025
Enrollment
12 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumour